D-Pharm Climbs Most in Two Weeks on Deal to Acquire Thrombotech

D-Pharm Ltd. rose the most in more than two weeks after the biopharmaceutical company reached an initial agreement to buy Thrombotech Ltd., which is developing a peptide that improves the efficiency of stroke medication.

The shares of the Nes Ziona, Israel-based company rose 8 percent, the biggest intraday advance since April 19, to 1.011 shekels at 3:11 p.m. in Tel Aviv.